STAT
AUGUST 8, 2024
How will we know if the the government gets a good deal in the first round of drug pricing negotiations? And has Allison thought about anything other than venture capital for the last couple of months? We discuss all that and more on this week’s episode of “The Readout LOUD.”
STAT
JUNE 7, 2023
BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JANUARY 23, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at some polarizing cancer data, a strange CEO transition, and the importance of New Year cheer. Read the rest…
STAT
AUGUST 7, 2023
A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics filed a lawsuit accusing Eli Lilly of undermining a project in favor of another deal.
STAT
FEBRUARY 9, 2024
Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs. Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a listen. Read the rest…
STAT
SEPTEMBER 26, 2023
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so can lead to its most significant revenue period, according to a recent analysis published by the Initiative for Medicines, Access & Knowledge, or I-MAK, a nonprofit advocating for drug pricing reforms.
STAT
FEBRUARY 1, 2024
Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing. In 2024, as in 2023, the industry’s fate seems inextricable from interest rates.
Expert insights. Personalized for you.
277 
Let's personalize your content